Beclometasone /formoterol (Fostair®) for COPD. HTA ID 23037

Assessment Status Rapid Review Complete
HTA ID 23037
Drug Beclometasone /formoterol
Brand Fostair®
Indication Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Assessment Process
Rapid review commissioned 10/07/2023
Rapid review completed 20/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.